KIMBERLY GRAVELY: Open Payments
NPI 1952998858 · MARTINSVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$314 in 18 payments from 10 companies in 2025. Trend: 2023 $76 · 2024 $366 · 2025 $314
Food & beverage: $314
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $77 |
| Gilead Sciences, Inc. | 3 | $50 |
| Lilly USA, LLC | 2 | $35 |
| Medtronic, Inc. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $28 |
| Dexcom, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: Rybelsus, MOUNJARO, SYNCHROMEDII, XIFAXAN, Ozempic, Dexcom G6 Transmitter, Wegovy, UBRELVY.
Industry payments across VA — which companies pay providers there.
